A modelling study suggests that the lenacapavir anti-HIV jab could potentially end Aids in South Africa by 2032 if between two and four million HIV-negative individuals use it annually over the next eight years. The key question raised is how much should be paid for the jab to make this ambitious goal a reality, highlighting the importance of affordability and accessibility in combating the HIV epidemic in the country.
Full Article
Loading PerspectiveSplit analysis...
